Piramal Pharma swings to ₹5 crore profit in Q2 as revenue rises 28%

What happened

Piramal Pharma reported a consolidated net profit of ₹5 crore for the July-September quarter, compared with a loss of ₹99.22 crore a year earlier. Revenue rose to ₹2,617.06 crore from ₹2,043.72 crore, while total expenses increased to ₹2,589.10 crore.

Confirmed

Global impact / market context

Turning a loss into a small profit shows the company now earns slightly more than it spends each quarter. Revenue rose 28%, which means sales grew much faster than costs, helping the business move from losing money to a modest gain for shareholders.

Analyst inference

The company's shares settled higher at ₹198.45 on the BSE, which means buyers pushed the price up on the day of the results. That suggests investors responded positively to the swing to profit and the strong revenue growth.

Analyst inference

What to watch

1. The reported ₹5 crore quarterly profit is very small compared with revenue of ₹2,617.06 crore, so a minor change in expenses could push the company back to a loss. Confirmed
2. Investors may want to watch whether total expenses keep growing faster than revenue in coming quarters, because that would squeeze the thin profit and reduce cash available for the business. Proposed
3. Because the company only just returned to profit, future capital spending plans and cost control will probably decide whether earnings grow, which could affect how investors value PPLPHARMA shares over time. Analyst inference

Evidence

• Original source link unavailable